Advertisement

Topics

AstraZeneca and Merck Rapidly Advance LYNPARZA® (olaparib) in Japan With a Second Regulatory ...

02:06 EDT 23 Oct 2017 | BioMedReports - Blog

Potential to Offer a New Treatment Option for Patients With Germline BRCA-mutated, HER2-negative Metastatic Breast Cancer

Read more...

Original Article: AstraZeneca and Merck Rapidly Advance LYNPARZA® (olaparib) in Japan With a Second Regulatory ...

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca and Merck Rapidly Advance LYNPARZA® (olaparib) in Japan With a Second Regulatory ..."

Advertisement
Quick Search
Advertisement
Advertisement